<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        7-262-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1988
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RENITEC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ENALAPRIL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Organon Pharma (UK) Limited " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Organon Pharma (UK) Limited 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ORGANON
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09AA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Renitec contains an active substance called enalapril maleate. This belongs to the group of medicines called ACE inhibitors (angiotensin converting enzyme inhibitors).</p><p>Renitec is used:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat high blood pressure (hypertension)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat heart failure (weakening of heart function). It can lower the need to go to hospital and can help some patients live longer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent the signs of heart failure. The signs include: shortness of breath, tiredness after light physical activity such as walking, or swelling of the ankles and feet.</p><p>&nbsp;</p><p>This medicine works by widening your blood vessels. This lowers your blood pressure. The medicine usually starts to work within an hour, and the effect lasts for at least 24 hours. Some people will require several weeks of treatment until the best effect on your blood pressure is seen.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Renitec</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to enalapril maleate or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had an allergic reaction to a type of medicine similar to this medicine called an ACE inhibitor</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had swelling of your face, lips, mouth, tongue or throat which caused difficulty in swallowing or breathing (angioedema) when the reason why was not known or it was inherited</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant. (It is also better to avoid Renitec in early pregnancy &ndash; see Pregnancy section.)</p><p>&nbsp;</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Renitec:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a heart problem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a condition involving the blood vessels in the brain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a blood problem such as low or lack of white blood cells (neutropenia/agranulocytosis), low blood platelet count (thrombocytopenia) or a decreased number of red blood cells (anaemia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a liver problem</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a kidney problem (including kidney transplantation). These may lead to higher levels of potassium in your blood which can be serious. Your doctor may need to adjust your dose of Renitec or monitor your blood level of potassium.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are having dialysis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have been very sick (excessive vomiting) or had bad diarrhoea recently</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are on a salt-restricted diet, are taking potassium supplements, potassium-sparing agents, or potassium-containing salt substitutes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are over 70 years of age</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes. You should monitor your blood for low blood glucose levels, especially during the first month of treatment. The level of potassium in your blood can also be higher.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had an allergic reaction with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing. You should be aware that black patients are at increased risk of these types of reactions to ACE inhibitors.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have low blood pressure (you may notice this as faintness or dizziness, especially when standing)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have collagen vascular disease (e.g., lupus erythematosus, rheumatoid arthritis or scleroderma), are on therapy that suppresses your immune system, are taking the drugs allopurinol or procainamide, or any combinations of these.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking an mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus: medicines used to treat certain types of cancer or to prevent the body&rsquo;s immune system from rejecting a transplanted organ). You may be at increased risk for an allergic reaction called angioedema.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking any of the following medicines used to treat high blood pressure:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an angiotensin II receptor blocker (ARB) (also known as sartans - for example valsartan, telmisartan, irbesartan, etc.), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aliskiren.</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.</p><p>&nbsp;</p><p>See also information under the heading &ldquo;Do not take Renitec.&rdquo;</p><p>&nbsp;</p><p>You must tell your doctor if you think you are (<u>or might become</u>) pregnant. This medicine is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see Pregnancy section).</p><p>&nbsp;</p><p>You should be aware that this medicine lowers the blood pressure in black patients less effectively than in non-black patients.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>If you are about to have a procedure</p><p>If you are about to have any of the following, tell your doctor that you are taking Renitec:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any surgery or receive anaesthetics (even at the dentist).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a treatment to remove cholesterol from your blood called &lsquo;LDL apheresis&rsquo;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a desensitisation treatment, to lower the effect of an allergy to bee or wasp stings.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the above applies to you, talk to your doctor or dentist before the procedure.</p><p>&nbsp;</p><p>Other medicines and Renitec</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines. This is because Renitec can affect the way some medicines work. Also some other medicines can affect the way Renitec works. Your doctor may need to change your dose and/or to take other precautions.</p><p>&nbsp;</p><p>In particular tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an angiotensin II receptor blocker (ARB) or aliskiren (see also information under the headings &ldquo;Do not take Renitec&rdquo; and &ldquo;Warnings and precautions&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to lower blood pressure, such as beta-blockers or water tablets (diuretics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines containing potassium (including dietary salt substitutes)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for diabetes (including oral antidiabetic medicines and insulin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium (a medicine used to treat a certain kind of depression)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for depression called &lsquo;tricyclic antidepressants&rsquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for mental problems called &lsquo;antipsychotic&rsquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain cough and cold medicines and weight reducing medicines which contain something called a &lsquo;sympathomimetic agent&rsquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain pain or arthritis medicines including gold therapy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus; medicines used to treat certain types of cancer or to prevent the body&rsquo;s immune system from rejecting a transplanted organ). See also information under the heading &ldquo;Warnings and precautions&rdquo;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatory drugs, including COX-2-inhibitors (medicines that reduce inflammation, and can be used to help relieve pain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aspirin (acetylsalicylic acid)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to dissolve blood clots (thrombolytics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alcohol</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Renitec.</p><p>&nbsp;</p><p>Renitec with food and drink</p><p>Renitec can be taken with or without food. Most people take Renitec with a drink of water.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p><u>Pregnancy</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will normally advise you to stop taking Renitec before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Renitec. This medicine is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. Breast-feeding newborn babies (first few weeks after birth), and especially premature babies, is not recommended whilst taking this medicine. In the case of an older baby your doctor should advise you on the benefits and risks of taking this medicine whilst breast-feeding, compared to other treatments.</p><p>&nbsp;</p><p>Driving and using machines</p><p>You may feel dizzy or sleepy while taking this medicine. If this happens, do not drive or use any tools or machines.</p><p>&nbsp;</p><p>Renitec contains lactose</p><p>Renitec contains lactose, which is a type of sugar. If you have been told by your doctor that you have intolerance to some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is very important to continue taking this medicine for as long as your doctor prescribes it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take more tablets than prescribed.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The score line is only there to help you break the tablet if you have difficulty swallowing it whole.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 2.5 mg is not possible with Renitec. Another suitable formulation should be used for a dose of 2.5 mg.</p><p>&nbsp;</p><p>&nbsp;</p><p>High Blood Pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual starting dose ranges from 5 to 20 mg taken once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some patients may need a lower starting dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual long term dose is 20 mg taken once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximal long term dose is 40 mg taken once a day.</p><p>&nbsp;</p><p>Heart Failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual starting dose is enalapril 2.5 mg taken once a day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will raise this amount step by step until the dose that is right for you has been achieved.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual long term dose is 20 mg each day, taken in one or two doses.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximal long term dose is 40 mg each day, divided in two doses.</p><p>&nbsp;</p><p>Patients with kidney problems</p><p>Your dose of medicine will be changed depending on how well your kidneys are working:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moderate kidney problems &ndash; 5 mg to 10 mg each day</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe kidney problems - enalapril 2.5 mg each day</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are having dialysis - enalapril 2.5 mg each day. On days you are not having dialysis, your dose may be changed depending on how low your blood pressure is.</p><p>&nbsp;</p><p>Elderly patients</p><p>Your dose will be decided by your doctor and will be based on how well your kidneys are working.</p><p>&nbsp;</p><p>Use in children</p><p>Experience in the use of Renitec in children with high blood pressure is limited. If the child can swallow tablets, the dose will be worked out using the child&rsquo;s weight and blood pressure. The usual starting doses are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; between 20 kg and 50 kg - enalapril 2.5 mg each day</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more than 50 kg &ndash; 5 mg each day.</p><p>The dose can be changed according to the needs of the child:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a maximum of 20 mg daily can be used in children who are between 20 kg and 50 kg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a maximum of 40 mg daily can be used in children who are more than 50 kg.</p><p>&nbsp;</p><p>This medicine is not recommended in newborn babies (first few weeks after birth) and in children with kidney problems.</p><p>&nbsp;</p><p>If you take more Renitec than you should</p><p>If you take more Renitec than you should, talk to your doctor or go to a hospital straight away. Take the medicine pack with you. The following effects may happen: feeling of light-headedness or dizziness. This is due to a sudden or excessive drop in blood pressure.</p><p>&nbsp;</p><p>If you forget to take Renitec</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a tablet, skip the missed dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the next dose as usual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop taking Renitec</p><p>Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Stop taking Renitec and talk to a doctor straight away, if you notice any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your face, lips, tongue or throat which may cause difficulty in breathing or swallowing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your hands, feet or ankles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you develop a raised red skin rash (hives).</p><p>You should be aware that black patients are at increased risk of these types of reactions. If any of the above happen, stop taking Renitec and talk to a doctor straight away.</p><p>&nbsp;</p><p>When you start taking this medicine you may feel faint or dizzy. If this happens, it will help to lie down. This is caused by your blood pressure lowering. It should improve as you continue to take the medicine. If you are worried, please talk to your doctor.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>Very Common </strong>(may affect more than 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, weak or sick</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough.</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; light-headedness due to low blood pressure, changes in heart rhythm, fast heartbeat, angina or chest pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, depression, fainting (syncope), change in sense of taste</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness (fatigue)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, allergic reactions with swelling of the face, lips, tongue or throat with difficulty in swallowing or breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high levels of potassium in the blood, increased levels of creatinine in your blood (both are usually detected by a test).</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden fall in blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or uneven heart beats (palpitations)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack (possibly due to very low blood pressure in certain high-risk patients, including those with blood flow problems of the heart or brain)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke (possibly due to very low blood pressure in high-risk patients)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia (including aplastic and haemolytic)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, sleeplessness or sleepiness, nervousness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling your skin prickling or being numb</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo (spinning sensation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in your ears (tinnitus)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny nose, sore throat or hoarseness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma-associated tightness in chest</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow movement of food through your intestine (ileus), inflammation of your pancreas</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting), indigestion, constipation, anorexia</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritated stomach (gastric irritations), dry mouth, ulcer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramps</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired kidney function, kidney failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching or nettle rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell (malaise), high temperature (fever)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of proteins in your urine (measured in a test)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of blood sugar or sodium, high level of blood urea (all measured in a blood test)</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;Raynaud&rsquo;s phenomenon&rsquo; where your hands and feet may become very cold and white due to low blood flow</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in blood values such as a lower number of white and red blood cells, lower haemoglobin, lower number of blood platelets</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone marrow depression</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen glands in neck, armpit or groin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; autoimmune diseases</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; strange dreams or sleep problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of fluid or other substances in the lungs (as seen on X-rays)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of your nose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs causing difficulty breathing (pneumonia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the cheeks, gums, tongue, lips, throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced amount of urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash that looks like targets (erythema multiforme)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lsquo;Stevens-Johnson syndrome&rsquo; and &lsquo;toxic epidermal necrolysis&rsquo; (serious skin conditions where you have reddening and scaling of your skin, blistering or raw sores), exfoliative dermatitis/erythroderma (severe skin rash with flaking or peeling of the skin), pemphigus (small fluid-filled bumps on the skin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver or gallbladder problems such as lower liver function, inflammation of your liver, jaundice (yellowing of the skin or eyes), high levels of liver enzymes or bilirubin (measured in a blood test)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlargement of breasts in males (gynaecomastia)</p><p>&nbsp;</p><p><strong>Very Rare </strong>(may affect up to 1 in 10,000 people)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling in your intestine (intestinal angioedema)</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; overproduction of antidiuretic hormone, which causes fluid retention, resulting in weakness, tiredness or confusion</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A symptom complex has been reported which may include some or all of the following: fever, inflammation of the blood vessels (serositis/vasculitis), muscle pain (myalgia/myositis), joint pain (arthralgia/arthritis). Rash, photosensitivity or other skin manifestations may occur.</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via (The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA). By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton after &lsquo;EXP&rsquo;.</p><p>Store below 30&deg;C. Store in the original package in order to protect from moisture.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste.&nbsp; Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is enalapril maleate (10 mg).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are Sodium hydrogen carbonate, corn starch, Pregelatinised corn starch,&nbsp;&nbsp;&nbsp; Magnesium stearate, Lactose hydrous The 10 mg tablet also contains iron oxide red (E172) and the 20 mg tablet also contains iron oxide red (E172) and iron oxide yellow (E172), Purified Water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                RENITEC 10 mg - All-aluminium blister packages containing 28, 49 x 1, 30, 50, 98 or 100 tablets.

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder</p><p>Merck Sharp &amp; Dohme B.V., Waarderweg 39, 2031 BN Haarlem</p><p>P.O. Box 581 , 2003 PC Haarlem,</p><p>The Nethterlands</p><p>&nbsp;</p><p>Manufacturer</p><p>Merck Sharp &amp; Dohme, Shotton Lane, Cramlington Northumberland NE23 3JU,</p><p>United Kingdom</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
This leaflet was last revised in Dec 2017.

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA
o Fax: +966-11-205-7662
o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.
o Toll free phone: 8002490000
o E-mail: npc.drug@sfda.gov.sa
o Website: www.sfda.gov.sa/npc
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.

Council of Arab Health Ministers 
Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food and Drug Authority

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي رينيتك على مادة فعالة تُعرَف باينالبريل ماليات، وهو دواء ينتمي إلى مجموعة أدوية تُعرَف بمثبطات الإنزيم المحوّل للأنجيوتنسين.</p><p>يُستخدَم رينيتك:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمعالجة إرتفاع ضغط الدم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمعالجة القصور القلبي (ضعف وظيفة القلب). يُمكن أن يحدّ من الحاجة إلى الذهاب إلى المستشفى ويُساعد بعض المرضى على العيش لمدّة أطول.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للوقاية من مؤشّرات القصور القلبي. من بين هذه المؤشّرات: ضيق النفس، والتعب بعد ممارسة نشاط جسدي خفيف مثل المشي، أو تورّم الكاحلَيْن والقدمَيْن.</p><p>&nbsp;</p><p>يعمل هذا الدواء على توسيع الأوعية الدمويّة، ممّا يُخفّض ضغط الدم. عادةً، يبدأ مفعول الدواء في غضون ساعة ويدوم لمدّة 24 ساعة على الأقل. يحتاج بعض المرضى إلى عدّة أسابيع من العلاج من أجل رؤية أفضل تأثير للدواء على ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم رينيتك في الحالات التالية:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي حساسيّة من اينالبريل ماليات أو من أي من المكوّنات الأخرى لهذا الدواء (المُدرَجة في البند 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي حساسيّة من دواء مشابه لهذا الدواء يُعرف بمثبطّات الإنزيم المحوّل للأنجيوتنسين.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرّضت لانتفاخ الوجه، أو الشفتَيْن، أو الفم، أو اللسان، أو الحنجرة، ما يُسبّب صعوبة في البلع أو التنفس (وذمة وعائيّة) عندما يكون السبب وراء ذلك مجهولاً أو وراثيًّا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت مصابًا بداء السكري أو بقصور في الكلى وكنت تتناول دواءً يحتوي على الأليسكيرين لتخفيض ضغط الدم.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت حاملاً لأكثر من 3 أشهر (من الأفضل أيضًا تفادي تناول رينيتك في فترة الحمل الأولى &ndash; راجعي قسم الحمل).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى علاج فالسارتان/ساكوبيتريل&nbsp; ، دواء لفشل القلب.</p><p>&nbsp;</p><p>لا تستخدم الدواء في حال كان أي ممّا سبق ينطبق عليك. في حال لم تكن متأكّدًا، اتّصل بالطبيب أو بالصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p><strong>التحذير والوقاية</strong></p><p>إتّصل بالطبيب أو بالصيدلي قبل تناول هذا الدواء.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في القلب</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في الأوعية الدمويّة للدماغ</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في الدم، مثلاً انخفاض كريّات الدم البيضاء أو غيابها (قلّة العدِلات ونقص في الكريّات البيضاء)، وانخفاض عدد لويحات الدم (قلّة الصفيحات)، أو انخفاض عدد كريّات الدم الحمراء (فقر دم)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في الكبد</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مشكلة في الكلى (بما في ذلك زرع كلى). قد يؤدّي ذلك إلى مستويات أعلى من البوتاسيوم في الدم قد تكون خطرة. قد يحتاج الطبيب إلى ضبط جرعة رينيتك أو مراقبة مستوى البوتاسيوم في دمك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لغسيل كلى.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مريضًا جدًّا (تقيّؤ مفرَط) أو أُصبت بالإسهال مؤخّرًا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع حميّة غذائيّة قليلة الملح أو تتناول مكمّلات البوتاسيوم، أو العوامل المدّخرة للبوتاسيوم، أو بدائل الملح التي تحتوي على البوتاسيوم أو أدوية أخرى قد ترفع البوتاسيوم في الدم (على سبيل المثال، الهيبارين [دواء يستخدم لمنع تجلطات الدم]، المنتجات التي تحتوي على التريميثوبريم مثل كوتريموزول [الأدوية المستخدمة لعلاج العدوى])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تجاوزت السبعين من عمرك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بداء السكري. عليك مراقبة انخفاض مستوى الجلوكوز في دمك، لا سيما في خلال الشهر الأول من العلاج. قد يكون مستوى البوتاسيوم أعلى أيضًا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال تعرّضت لأي حساسيّة مع انتفاخ الوجه، أو الشفتَيْن، أو اللسان، و/أو الحنجرة وصعوبة في البلع أو التنفس. عليك أن تعي أن المرضى &nbsp;اصحاب البشرة السوداء معرّضون بشكل أكبر لخطر الإصابة بردود الفعل هذه من مثبّطات الإنزيم المحوّل للأنجيوتنسين.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني انخفاضًا في ضغط الدم (يُمكنك ملاحظة ذلك عند فقدان الوعي أو الشعور بالدوران، لا سيّما عند الوقوف).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر الطبيب في حال كنت مصابًا بمرض وعائي كولاجيني (مثلاً ذئبة حمائيّة، أو التهاب المفاصل الروماتويدي، أو تصلّب الجلد)، أو في حال كنت تخضع لعلاج يثبط نظام مناعتك، أو تتناول أدوية آلوبورينول أو بروكاييناميد، أو أي توليفة من الاثنَيْن.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تأخذ مثبط mTOR (على سبيل المثال، تيمسيروليمس، سيروليمس، أو ايفيروليموس: الأدوية المستخدمة لعلاج أنواع معينة من السرطان أو لمنع نظام المناعة في الجسم من رفض العضو المزروع). أو دواء يحتوي علي مثبط نيبريليسين مثل ساكوبيتريل &nbsp;(المتاح كتركيبه الجرعة الثابتة مع فالسارتان) ، ويستخدم في المرضي الذين يعانون من قصور القلب ، والراسيكادوتريل ، ويستخدم في المرضي الذين يعانون من الإسهال الحاد.قد تكون في خطر متزايد لرد فعل تحسسي يدعى وذمة وعائية.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أيًا من الأدوية التالية المستخدمة لمعالجة ارتفاع ضغط الدم:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات مستقبلات الأنجيوتنسين من النوع الثاني (المعروفة أيضًا بالسارتان &ndash; مثلاً، فالسارتان، تلميسارتان، إربيسارتان، إلخ.)، بشكل خاص إذا كنت تعاني مشاكل كلويّة مرتبطة بالسكري.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأليسكيرين</p><p>&nbsp;</p><p>قد يتأكّد الطبيب من وظيفة الكلى، وارتفاع ضغط الدم، وكميّة الأملاح (مثلاً البوتاسيوم) في الدم بشكل منتظم.</p><p>راجع أيضًا المعلومات تحت القسم &quot;لا تتناول رينيتك&quot;.</p><p>&nbsp;</p><p>أخبري الطبيب إذا كنتِ تظنّين أنّك حاملًأ (<u>أو قد تصبحين حاملًا</u>).لا يُوصى بتناول هذا الدواء في بداية الحمل ويجب عدم تناوله في حال كنتِ حاملًا لأكثر من 3 أشهر، بما أنّه قد يُلحق أذًى خطيرًا بطفلك في حال تناوله في هذه المرحلة (راجع قسم الحمل).</p><p>&nbsp;</p><p>يجب أن تعي أن هذا الدواء يخفّض ضغط الدم لدى المرضى أصحاب البشرة السوداء بشكل أقلّ فاعليّة مقارنةً مع المرضى &nbsp;أصحاب البشرة الفاتحة.</p><p>&nbsp;</p><p>في حال لم تكن متأكّدًا إذا كان ما هو وارد أعلاه ينطبق عليك، تحدّث إلى الطبيب أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p><strong>إذا كنت على وشك الخضوع لعمليّة</strong></p><p>في حال كنت على وشك الخضوع لأي من الحالات التالية، أخبر الطبيب على أنّك تتناول رينيتك:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخضوع لأي جراحة أو الخضوع للتخدير (حتى لدى طبيب الأسنان)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج لإزالة الكولسترول من دمك، يُعرَف بفصادة بروتين شَحْمِي خَفيض.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج إزالة التحسّس للحدّ من أثر الحساسيّة من لسعات النحل أو الدبابير.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال كانت أيّ حالة من الحالات الواردة أعلاه تنطبق عليك، تحدّث إلى الطبيب أو الصيدلي قبل الخضوع للإجراء.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى ورينيتك&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p>أخبر الطبيب أو الصيدلي إذا كنت تتناول، أو تناولت مؤخّرًا، أو قد تتناول أيّ أدوية أخرى. يشمل ذلك الأدوية العشبيّة. حيث أن رينيتك يؤثّر على طريقة عمل بعض الأدوية. كما يُمكن لبعض الأدوية الأخرى أن تؤثر على طريقة عمل رينيتك. قد يطلب منك الطبيب تبديل جرعتك و/أو اتّخاذ إجراءات وقائيّة أخرى.</p><p>بشكل خاص، تحدّث إلى الطبيب أو الصيدلي في حال كنت تتناول أيًّا من الأدوية التالية:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات مستقبلات الأنجيوتنسين أو دواء يُعرَف بالأليسكيرين (راجع أيضًا المعلومات في البندين &quot;لا تتناول رينيتك&quot; و&quot;التحذير والوقاية&quot;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لتخفيض ضغط الدم، مثل مثبطات البيتا أو أقراص الماء (مدرّات البول)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تحتوي على البوتاسيوم (بما في ذلك بدائل الملح الغذائيّة) أو أدوية أخرى قد ترفع البوتاسيوم في الدم (على سبيل المثال، الهيبارين [دواء يستخدم لمنع تجلطات الدم]، المنتجات التي تحتوي على التريميثوبريم مثل كوتريموزول [الأدوية المستخدمة لعلاج العدوى])</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لمعالجة داء السكري (بما في ذلك الإنسولين والأدوية الفمويّة المضادة للسكري)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يُستخدَم لمعالجة نوع من الكآبة)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب الثلاثيّة الحلقات (أدوية لمعالجة الاكتئاب)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المُضادة للذهان (أدوية تُستخدَم لمعالجة انفصام الشخصيّة)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية الرّشح والسّعال والأدوية المخفّضة للوزن التي تحتوي على ما يُعرف بـ&quot;عامل مُحاكٍ ودي&quot;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بعض الأدوية لمعالجة الألم والتهاب المفاصل، بما في ذلك العلاج بالذهب</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبط mTOR (على سبيل المثال، تيمسيروليمس، سيروليمس، أو ايفيروليموس: الأدوية المستخدمة لعلاج أنواع معينة من السرطان أو لمنع نظام المناعة في الجسم من رفض العضو المزروع). قد تكون في خطر متزايد لرد فعل تحسسي يدعى وذمة وعائية.</p><p>أنظر أيضًا إلى المعلومات المدرجة تحت (التحذير والوقاية).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دواء يحتوي علي مثبط نيبريليسين مثل ساكوبيتريل (المتاح كتركيبه الجرعة الثابتة مع فالسارتان) و راسيكادوتريل . يمكن زيادة خطر الوذمه الوعائية (تورم الوجه أو الشفتين أو اللسان أو الحلق مع صعوبة في البلع أو التنفس). انظر أيضا المعلومات الواردة تحت العناوين &quot;لا تتناول رينيتك &quot; و &quot;التحذيرات والاحتياطات&quot;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التهاب لاستيرويدية، بما في ذلك مثبّطات سيكلو أوكسيجيناز 2 (أدوية تحدّ من الالتهاب ويُمكن استخدامها من أجل التخفيف من الألم)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسبيرين (حمض الأسيتيل ساليسيليك)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُستخدم لتذويب التخثرات الدمويّة (أدوية مذيبة للخثرات)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحول</p><p>&nbsp;</p><p>في حال لم تكن متأكّدًا إن كان ما وهو وارد أعلاه ينطبق عليك، تحدّث إلى الطبيب أو الصيدلي قبل تناول رينيتك.</p><p>&nbsp;</p><p><strong>رينيتك مع الأطعمة والمشروبات</strong></p><p>يُمكن تناول رينيتك مع أطعمة أو من دونها. غالبيّة الناس يتناولون رينيتك مع شرب الماء.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة</strong></p><p><u>الحمل</u></p><p>إذا كنت حاملًا أو ترضعين، أو تظنّين أنّك قد تكونين حاملًا أو أنّك تُخطّطين للإنجاب، استشيري طبيبك قبل تناول هذا الدواء. ينصحك طبيبك عادةً بالتوقّف عن تناول رينتيك قبل أن تُصبحي حاملًا أو ما أن تعرفي أنّكِ حامل وبتناول دواء آخر بدل رينيتك. لا يوصى بتناول هذا الدواء في خلال فترة الحمل الأولى ويجب عدم تناوله عند تجاوز الشهر الثالث من الحمل بما أنّه قد يُلحق أذًى خطيرًا بطفلك في حال استخدامه بعد الشهر الثالث من الحمل.</p><p>&nbsp;</p><p><u>الرضاعة</u></p><p>أخبري الطبيب إذا كنتِ ترضعين أو على وشك البدء بالرضاعة. لا يُوصى بإرضاع الأطفال حديثي الولادة (الأسابيع الأولى بعد الولادة)، لا سيّما الأطفال الذين ولدوا قبل أوانهم (الخُدَّج) وأنتِ تتناولين هذا الدواء. في حال إرضاع طفل أكبر، على طبيبك أن ينصحك بشأن المنافع والمخاطر لتناول هذا الدواء في خلال الإرضاع، مقارنةً مع علاجات أخرى.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآليّات</strong></p><p>قد تشعر بالدوران أو بالنعاس عند تناول هذا الدواء. في هذه الحالة، لا تقُد أو تستخدم أي أدوات أو آليّات.</p><p>&nbsp;</p><p><strong>رينيتك يحتوي على اللاكتوز</strong></p><p>يحتوي رينيتك على اللاكتوز، وهو نوع من السكريّات. إذا قال لك الطبيب إنّك لا تتقبَّل بعض السكريّات، اتّصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائمًا هذا الدواء بناءً على وصفة الطبيب أو الصيدلي. راجع الطبيب أو الصيدلي في حال لم تكن متأكّدًا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;من المهمّ جدًا متابعة تناول هذا الدواء للفترة التي وصفها الطبيب لك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لا تتناول عدد أقراص أكثر من الجرعة الموصوفة لك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخط المُحزز السطر موجود فقط لمساعدتك على كسر القرص إذا كانت لديك صعوبة في ابتلاع القرص كاملاً.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جرعة 2.5 ملغم غير ممكنة من رينيتيك. ينبغي أن تستخدم تركيبة مناسبة أخرى لجرعة 2.5 ملغم.</p><p>&nbsp;</p><p><strong>ارتفاع ضغط الدم</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتراوح الجرعة الأولية الاعتياديّة بين 5 و20 ملغم، مرة واحدةً يوميًّا</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتاج بعض المرضى إلى جرعة أوليّة أدنى</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الاعتياديّة الطويلة الأمد 20 ملغم مرةً واحدةً يوميًا</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة القصوى الطويلة الأمد 40 ملغم مرةً واحدةً يوميًا</p><p>&nbsp;</p><p><strong>قصور في القلب</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الأوليّة الاعتياديّة اينالبريل 2.5 ملغم مرةً واحدةً يوميًّا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيزيد الطبيب الجرعة تدريجيًّا حتى بلوغ الجرعة الملائمة لك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الجرعة الاعتياديّة الطويلة الأمد 20 ملغم يوميًا، في جرعة أو جرعتَيْن.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الجرعة القصوى الطويلة الأمد 40 ملغم، موزّعة على جرعتَيْن.</p><p>&nbsp;</p><p><strong>المرضى المصابون بمشاكل في الكلى</strong></p><p>يتمّ تعديل جرعة الدواء وفق مستوى عمل الكلى:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل كلى معتدلة &ndash; 5 ملغم إلى 10 ملغم كل يوم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مشاكل كلى حادة &ndash; اينالبريل 2.5 ملغم يوميًّا</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع لغسيل كلى &ndash; اينالبريل 2.5 ملغم يوميًا. في الأيام التي لا تخضع فيها لغسيل كلى، يُمكنك تعديل جرعتك حسب مستوى انخفاض ضغط دمك.</p><p>&nbsp;</p><p><strong>المرضى كبار السن</strong></p><p>يُحدّد الطبيب الجرعة المناسبة لك على أساس مستوى عمل كُليتَيْك.</p><p>&nbsp;</p><p><strong>الاستخدام لدى الأطفال</strong></p><p>تجربة استخدام رينيتك لدى الأطفال المصابين بضغط دم مرتفع محدودة. في حال كان الطفل قادرًا على ابتلاع الأقراص، يتمّ تنظيم الجرعة على أساس وزن الطفل وضغط دمه. تكون الجرعات الأوليّة الاعتياديّة على الشكل التالي:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بين 20 كلغ و50 كلغ &ndash; اينالبريل 2.5 ملغم كل يوم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أكثر من 50 كلغ &ndash; 5 ملغم كل يوم</p><p>يُمكن تعديل الجرعة وفق حاجات الطفل.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن استخدام الجرعة القصوى 20 ملغم يوميًا لدى الأطفال الذين يتراوح وزنهم بين 20 و50 كلغ.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن استخدام الجرعة القصوى 40 ملغم يوميًّا لدى الأطفال الذين يتجاوز وزنهم 50 كلغ.</p><p>لا يوصى بإعطاء هذا الدواء إلى الأطفال حديثي الولادة (في الأسابيع الأولى بعد الولادة) ولدى الأطفال المصابين بمشاكل في الكُلى.</p><p>&nbsp;</p><p><strong>في حال تناول جرعة زائدة من رينيتك </strong></p><p>في حال تناول جرعة زائدة، اتّصل بطبيبك على الفور أو اذهب إلى المستشفى فورًا. خُذْ علبة الدواء معك.</p><p>قد تظهر العوارض التالية: الشعور بالدوران أو الدوخة<strong> </strong>بسبب انخفاض مفاجئ أو مفرط في ضغط الدم.</p><p>&nbsp;</p><p><strong>في حال نسيت تناول رينيتك </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال نسيت تناول قرص، فوّت الجرعة التي نسيتها.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خُذْ الجرعة التالية كالمعتاد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مُضاعفة للتعويض عن جرعة نسيتها.</p><p>&nbsp;</p><p><strong>في حال التوقّف عن تناول رينيتك </strong></p><p>لا تتوقّف عن تناول الدواء إلاّ إذا طلب الطبيب منك ذلك.</p><p>في حال كان لديك أي سؤال إضافي حول استخدام هذا الدواء، إطرحه على الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>على غرار الأدوية كلّها، يُمكن أن يُسبّب هذا الدواء أعراض جانبيةً، وإن كانت لا تُصيب الجميع.</p><p>قد تظهر االأعراض الجانبيّة التالية عند تناول هذا الدواء.</p><p><strong>توقّف عن تناول رينيتك واتّصل بالطبيب فورًا في حال لاحظت أيًّا من االأعراض التالية:</strong></p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انتفاخ الوجه والشفتَيْن واللسان أو الحنجرة، ما قد يُسبّب صعوبةً في التنفّس أو البلع.</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>انتفاخ اليدَيْن أو القدمَيْن أو الكاحلَيْن</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>في حال الإصابة بطفح جلدي يُسبّب الاحمرار (الشرى).</p><p><strong>&nbsp;</strong></p><p>يجب أن تعي أن المرضى أصحاب البشرة السوداء معرّضون بشكل أكبر لردود الفعل هذه. في حال حدوث أي من الحالات الواردة أعلاه، توقّف عن تناول رينيتك واتصّل بالطبيب فورًا.</p><p>&nbsp;</p><p>عندما تبدأ بتناول هذا الدواء، قد تشعر بالدوران أو تفقد الوعي. في هذه الحالة، قد يُساعدك الاستلقاء، وذلك بسبب انخفاض ضغط الدم لديك. يجب أن يتحسّن ضغط دمك عندما تتناول الدواء. في حال كنت قلقًا، يُرجى الاتصال بالطبيب.</p><p>&nbsp;</p><p>تشمل الأعراض الجانبيّة الأخرى:</p><p>الأعراض الشائعة جدًّا (لدى أكثر من مريض واحد من أصل 10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوران، أو الضعف، أو المرض</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تغيّم الرؤية</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;السُّعَال</p><p>&nbsp;</p><p>الشائعة (لدى مريض واحد من أصل 10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدُّوَار الخفيف بسبب انخفاض ضغط الدم، تغيرات في نظم القلب، تسارع دَقّات القلب، ذبحة أو ألم في الصدر، صداع، فقدان الوعي (الإغماء) ، الاكتئاب</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبدّل حاسّة الذوق، ضيق النفس</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو الألم المعدي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب (الوهن)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، ردود الفعل الحساسيّة مع انتفاخ الوجه، أو الشفتَيْن، أو اللسان أو الحنجرة وصعوبة في البلع أو التنفّس</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى البوتاسيوم في الدم، زيادة مستوى الكرياتينين في الدم (يتمّ رصدهما في فحص عادةً).</p><p>&nbsp;</p><p>غير شائعة (لدى مريض واحد من أصل 100):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إحمرار الوجه</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ في ضغط الدم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع دَقّات القلب أو دَقّات قلب غير منتظمة ( خفقان)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبيّة (ربّما بسبب ضغط الدم المنخفض جدًّا لدى بعض المرضى ذوي المخاطر المرتفعة، بما في ذلك الذين لديهم مشاكل في تدفّق الدم إلى القلب أو الدماغ)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سكتة (ربّما بسبب ضغط دم منخفض جدًا لدى المرضى ذوي المخاطر العالية)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فقر الدم (بما في ذلك فقر الدم اللاتنسجي والانحلالي)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الارتباك، الأرق أو النعاس، التوتّر</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الشعور بوخز في جلدك أو بالتنميل</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الدوخة (الشعور بالدوران)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الطنين في الأذنَيْن</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الرّشح، الألم في الحنجرة، أو بحّة في الصوت</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ضيق الصدر الناتج عن الربو</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;بطء حركة الأطعمة في الأمعاء، التهاب البنكرياس</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (التقيؤ)، عسر الهضم، الإمساك، القهم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيّجات المعديّة، &nbsp;جفاف الفم، التقرّح، التشنّجات العضليّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قصور في وظيفة الكلى، فشل كلوي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ازدياد التعرّق</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الحكة أو &nbsp;طفح اللسعات</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فقدان الشعر</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الشعور العام بالاعياء، ارتفاع حرارة الجسم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;العجز الجنسي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مستوى مرتفع من البروتين في البول (يتمّ قياسه في فحص)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مستوى منخفض للصوديوم أو السكر في الدم، مستوى مرتفع ليوريا الدم (يتمّ قياسهما في فحص دم)</p><p>&nbsp;</p><p>نادرة (لدى مريض واحد من أصل 1000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظاهرة رينو( تبرد يداك وقدماك بشكل كبير فتصبح بيضاء بسبب انخفاض تدفّق الدم إليها )</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في عدد خلايا الدم، مثلاً انخفاض عدد الكريّات البيضاء والحمراء وانخفاض الهيموغلوبين وانخفاض عدد صفيحات الدم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض النخاع العظمي</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الغدد في العنق، أو تحت الإبط ، أو الأربيّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض المناعة الذاتيّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأحلام الغريبة ومشاكل النوم</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدّس السوائل أو المواد الأخرى في الرئتَيْن (كما هو واضح في التصوير بالأشعّة)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتَيْن، ممّا يُسبّب صعوبة في التنفّس (التهاب رئوي)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إلتهاب الخدَّيْن، واللثّة، واللسان، والشفتَيْن، والحنجرة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كميّة البول</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمامى العديدة الأشكال</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفينس &ndash; جونسون، وتَقَشُّرُ الأَنْسِجَةِ الميتة السُميّة (حالة جلديّة خطيرة مع إحمرار الجلد وتقشيره، وظهور البثور أو التقرّحات)، أو انفصال الطبقة العلويّة للبشرة عن الطبقات السفليّة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد/ احْمِرارُ الجِلْد (طفح جلدي حاد مع تقشير البشرة)، الفُقاعات (حبوب صغيرة على الجلد ممتلئة بسوائل)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل كبد أو مرارة، مثل انخفاض وظيفة الكبد، والتهاب الكبد، واليرقان (اصفرار الجلد أو العينَيْن)، مستويات أعلى من إنزيمات الكبد أو البيليروبين (يتمّ قياسها من خلال فحص دم)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي لدى الذكور</p><p>&nbsp;</p><p>نادرة جدًّا (لدى مريض واحد من أصل 10000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الأمعاء (وذمة وعائيّة معويّة)</p><p>&nbsp;</p><p>غير معروفة (لا يُمكن تحديد الوتيرة من البيانات المتوفّرة)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإنتاج المفرط لهرمون مضاد لإدرار البول، يُسبّب احتباس السوائل، ممّا يُسبّب الوهن، أو التعب، أو الارباك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمّ الابلاغ عن مجموعة &nbsp;من الأعراض، قد تشمل بعض ما يلي أو كلّه: الحمى، التهاب الأوعية الدموية (الْتِهابُ المَصْلِيَّة/ التهاب الأوعية الدّمويّة)، ألم في العضلات (أَلَمٌ عَضَلِيّ/اِلْتِهابُ العَضَل)، ألم مفاصل (أَلَمٌ مَفْصِلِيّ/التهاب المفصل). قد يبرز طفح جلدي، أو حساسيّة من الضوء أو أعراض جلديّة.</p><p>&nbsp;</p><p><strong>الإبلاغ عن الأعراض الجانبيّة</strong></p><p>في حال تعرّضت لأي أعراض جانبيّة، تحدّث إلى الطبيب أو الصيدلي. يشمل ذلك أي أعراض جانبيّة محتملة غير مدرجة في هذه النشرة. يمكنك الإبلاغ عن الأعراض الجانبية عن طريق &quot;المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء&quot; المذكور في بند &quot;للإبلاغ عن الأعراض الجانبية&quot;. من خلال إبلاغك عن الأعراض الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.</p><p>لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحيّة الوارد على الشريط أو العلبة بعد عبارة EXP.</p><p>يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية. يُحفظ في العبوة الأصلية لحمايته من الرطوبة.</p><p>لا ترمِ أي دواء في مياه الصرف الصحي أو في النفايات المنزليّة. اسأل الصيدلي عن كيفيّة التخلّص من الأدوية التي لم تعد تستخدمها. من شأن هذه الإجراءات مساعدتك على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعّالة هي اينالبريل ماليات&nbsp; 10&nbsp; ملغم).</p><p>- المكوّنات الأخرى هي كاربونات هيدروجين الصوديوم، ونشاء الذرة، ونشاء الذرة قبل التهلّم، وسترات المغنزيوم ،هيدروز اللاكتوز، كما يحتوي القرص 10 ملغم على أكسيد الحديد الأحمر (E172) والقرص 20 ملغم على أكسيد الحديد الأحمر (E172) وأكسيد الحديد الأصفر (E172)، الماء النقي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>رينيتك 10 ملغم &ndash; أشرطة ألومينيوم تحتوي على 28، 49 * 1، 30، 50، 98، أو 100 قرص. لا يتمّ تسويق أحجام العلب كلّها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>ميرك شارب و دوم بي. في.،</p><p>واردرويج ٣٩،٢٠٣۱ بي ان هارلم،</p><p>صندوق بريد ٥٨۱ ، ٢۰۰٣ بي سي</p><p>هولندا</p><p><strong>&nbsp;</strong></p><p><strong>الشركة الصانعة:</strong></p><p>ميرك شارب ودوم، شوتون لين، كراملينجتون، نورثمبرلاند، إن إي ٣٣٢جي يو،</p><p>المملكة المتحدة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ { أبريل 2019}

للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء
فاكس: +966-11-205-7662
للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات . هاتف: +966-11-20382222	
تحويلة: 2317-2356-2353-2354-2334-2340
الهاتف المجاني: 8002490000  
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: www.sfda.gov.sa/npc
•	دول الخليج الأخرى
الرجاء الإتصال بالمؤسسات و الهيئات الوطنية في كل دولة.



(ان هذا الدواء)
- الدواء مستحضر يؤثر على صحتك و استهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب و طريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب و الصيدلي هما الخبيران بالدواء و بنفعه و ضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الاطفال
مجلس وزراء الصحة العرب
و اتحاد الصيادلة العرب
     تمت الموافقة على نشرة المعلومات هذه الخاصة بالمريض من قبل الهيئة العامة الغذاء والدواء السعودية

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Renitec 5 mg Tablets
Renitec 10 mg Tablets Renitec
 20 mg Tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Renitec 5 mg
Each tablet contains 5 mg of enalapril maleate.
Excipient: each tablet contains 198 mg of lactose monohydrate. 

Renitec 10 mg
Each tablet contains 10 mg of enalapril maleate.
Excipient: each tablet contains 164 mg of lactose monohydrate. 

Renitec 20 mg
Each tablet contains 20 mg of enalapril maleate.
Excipient: each tablet contains 154 mg of lactose monohydrate.

Excipient(s) with known effect:
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Tablets.

Renitec 5 mg tablets are white, rounded triangle shaped tablet, one side scored* the other side marked ‘MSD 712’.
Renitec 10 mg tablets are rust red, rounded triangle shaped tablet, one side scored*, the other side marked ‘MSD 713’.
Renitec 20mg tablets are peach, rounded triangle shaped tablet, one side scored*, the other side marked ‘MSD 714’.

*The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of Hypertension</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment of Symptomatic Heart Failure</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention of Symptomatic Heart Failure in patients with Asymptomatic Left Ventricular Dysfunction (ejection fraction &le;35%)</p><p>&nbsp;</p><p>(See section 5.1.)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The absorption of Renitec Tablets is not affected by food.</p><p>&nbsp;</p><p>The dose should be individualised according to patient profile (see section 4.4) and blood pressure response.</p><p>&nbsp;</p><p><em>Paediatric Population</em></p><p>There is limited clinical trial experience of the use of Renitec in hypertensive paediatric patients (see sections 4.4, 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Hypertension</em></p><p>The initial dose is 5 to maximally 20 mg, depending on the degree of hypertension and the condition of the patient (see below). Renitec is given once daily. In mild hypertension, the recommended initial dose is 5 to 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (e.g., renovascular hypertension, salt and/or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 5 mg or lower is recommended in such patients and the initiation of treatment should take place under medical supervision.</p><p>&nbsp;</p><p>Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril. A starting dose of 5 mg or lower is recommended in such patients. If possible, diuretic therapy should be discontinued for 2-3 days prior to initiation of therapy with Renitec. Renal function and serum potassium should be monitored<em>.</em></p><p><em>&nbsp;</em></p><p>The usual maintenance dose is 20 mg daily. The maximum maintenance dose is 40 mg daily.</p><p>&nbsp;</p><p><em>Heart Failure/Asymptomatic Left Ventricular Dysfunction</em></p><p>In the management of symptomatic heart failure, Renitec is used in addition to diuretics and, where appropriate, digitalis or beta-blockers. The initial dose of enalapril in patients with symptomatic heart failure or asymptomatic left ventricular dysfunction is 2.5 mg, and it should be administered under close medical supervision to determine the initial effect on the blood pressure. In the absence of, or after effective management of, symptomatic hypotension following initiation of therapy with Renitec in heart failure, the dose should be increased gradually to the usual maintenance dose of 20 mg, given in a single dose or two divided doses, as tolerated by the patient. This dose titration is recommended to be performed over a 2 to 4 week period. The maximum dose is 40 mg daily given in two divided doses.</p><p>&nbsp;</p><p>Table 1: Suggested Dosage Titration of Renitec in Patients with Heart Failure/Asymptomatic Left Ventricular Dysfunction</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong><strong> </strong><strong>mg/day</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Week 1</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Days</strong><strong> 1 to 3: </strong>2.5 mg/day* in a single dose</p><p><strong>Days</strong><strong> 4 to 7: </strong>5 mg/day in two divided doses</p></td></tr><tr><td style="vertical-align:top"><p>Week 2</p></td><td style="vertical-align:top"><p>10 mg/day in a single dose or in two divided doses</p></td></tr><tr><td style="vertical-align:top"><p>Weeks 3 and 4</p></td><td style="vertical-align:top"><p>20 mg/day in a single dose or in two divided doses</p></td></tr></tbody></table><p>*&nbsp; Special precautions should be followed in patients with impaired renal function or taking diuretics (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>Blood pressure and renal function should be monitored closely both before and after starting treatment with Renitec (see section 4.4) because hypotension and (more rarely) consequent renal failure have been reported. In patients treated with diuretics, the dose should be reduced if possible before beginning treatment with Renitec. The appearance of hypotension after the initial dose of Renitec does not imply that hypotension will recur during chronic therapy with Renitec and does not preclude continued use of the drug. Serum potassium and renal function also should be monitored.</p><p>&nbsp;</p><p><em>Dosage in Renal Insufficiency</em></p><p>Generally, the intervals between the administration of enalapril should be prolonged and/or the dosage reduced.</p><p>&nbsp;</p><p>Table 2: Dosage in Renal Insufficiency</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine</strong><strong> Clearance (CrCL) mL/min</strong></p></td><td style="vertical-align:top"><p><strong>Initial Dose mg/day</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>30&lt;CrCL&lt;80 ml/min.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5 - 10 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>10&lt;CrCL&pound;30 ml/min.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.5 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>CrCL&pound;10 ml/min.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.5 mg on dialysis days*</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp; See section 4.4. Enalaprilat is dialysable. Dosage on nondialysis days should be adjusted depending on the blood pressure response.</p><p>&nbsp;</p><p><em>Use in Elderly</em></p><p>The dose should be in line with the renal function of the elderly patient (see section 4.4).</p><p>&nbsp;</p><p><em>Use in Paediatrics</em></p><p>For patients who can swallow tablets, the dose should be individualised according to patient profile and blood pressure response. The recommended initial dose of enalapril is 2.5 mg in patients 20 to &lt;50 kg and 5 mg in patients &ge;50 kg. Renitec is given once daily. The dosage should be adjusted according to the needs of the patient to a maximum of 20 mg daily in patients 20 to &lt;50 kg and 40 mg in patients</p><p>&ge;50 kg (see section 4.4.).</p><p>&nbsp;</p><p>Renitec is not recommended in neonates and in paediatric patients with glomerular filtration rate</p><p>&lt;30 ml/min/1.73 m2, as no data are available. <u>Method of administration</u></p><p>Oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
•	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or any other ACE inhibitor
•	History of angioedema associated with previous ACE inhibitor therapy
•	Hereditary or idiopathic angioedema
•	Second and third trimesters of pregnancy (see sections 4.4 and 4.6).





 
•	The concomitant use of Renitec with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Symptomatic Hypotension</u></p><p>Symptomatic hypotension is rarely seen in uncomplicated hypertensive patients. In hypertensive patients receiving Renitec, symptomatic hypotension is more likely to occur if the patient has been volume - depleted, e.g., by diuretic therapy, dietary salt restriction, dialysis, diarrhoea or vomiting (see sections 4.5 and 4.8). In patients with heart failure, with or without associated renal insufficiency, symptomatic hypotension has been observed. This is most likely to occur in those patients with more severe degrees of heart failure, as reflected by the use of high doses of loop diuretics, hyponatraemia or functional renal impairment. In these patients, therapy should be started under medical supervision and the patients should be followed closely whenever the dose of Renitec and/or diuretic is adjusted. Similar considerations may apply to patients with ischaemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.</p><p>&nbsp;</p><p>If hypotension occurs, the patient should be placed in the supine position and, if necessary, should receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which can be given usually without difficulty once the blood pressure has increased after volume expansion.</p><p>&nbsp;</p><p>In some patients with heart failure who have normal or low blood pressure, additional lowering of systemic blood pressure may occur with Renitec. This effect is anticipated, and usually is not a reason to discontinue treatment. If hypotension becomes symptomatic, a reduction of dose and/or discontinuation of the diuretic and/or Renitec may be necessary.</p><p>&nbsp;</p><p><u>Aortic or Mitral Valve Stenosis/Hypertrophic Cardiomyopathy</u></p><p>As with all vasodilators, ACE inhibitors should be given with caution in patients with left ventricular valvular and outflow tract obstruction and avoided in cases of cardiogenic shock and haemodynamically significant obstruction.</p><p>&nbsp;</p><p><u>Renal Function Impairment</u></p><p>In cases of renal impairment (creatinine clearance &lt;80 ml/min) the initial enalapril dosage should be adjusted according to the patient&rsquo;s creatinine clearance (see section 4.2) and then as a function of the patient&rsquo;s response to treatment. Routine monitoring of potassium and creatinine are part of normal medical practice for these patients.</p><p>&nbsp;</p><p>Renal failure has been reported in association with enalapril and has been mainly in patients with severe heart failure or underlying renal disease, including renal artery stenosis. If recognised promptly and treated appropriately, renal failure when associated with therapy with enalapril is usually reversible.</p><p>&nbsp;</p><p>Some hypertensive patients, with no apparent pre-existing renal disease have developed increases in blood urea and creatinine when enalapril has been given concurrently with a diuretic. Dosage reduction of enalapril and/or discontinuation of the diuretic may be required. This situation should raise the possibility of underlying renal artery stenosis (see section 4.4, <u>Renovascular hypertension</u>).</p><p>&nbsp;</p><p><u>Renovascular hypertension</u></p><p>There is an increased risk of hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with ACE inhibitors. Loss of renal function may occur with only mild changes in serum creatinine. In these patients,</p><p>&nbsp;</p><p>&nbsp;</p><p>therapy should be initiated under close medical supervision with low doses, careful titration, and monitoring of renal function.</p><p>&nbsp;</p><p><u>Kidney Transplantation</u></p><p>There is no experience regarding the administration of Renitec in patients with a recent kidney transplantation. Treatment with Renitec is therefore not recommended.</p><p>&nbsp;</p><p><u>Hepatic failure</u></p><p>Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice or hepatitis and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p><p>&nbsp;</p><p><u>Neutropenia/Agranulocytosis</u></p><p>Neutropenia/agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors. In patients with normal renal function and no other complicating factors, neutropenia occurs rarely. Enalapril should be used with extreme caution in patients with collagen vascular disease, immunosuppressant therapy, treatment with allopurinol or procainamide, or a combination of these complicating factors, especially if there is pre-existing impaired renal function. Some of these patients developed serious infections which in a few instances did not respond to intensive antibiotic therapy. If enalapril is used in such patients, periodic monitoring of white blood cell counts is advised and patients should be instructed to report any sign of infection.</p><p>&nbsp;</p><p><u>Hypersensitivity/Angioneurotic Oedema</u></p><p>Angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including Renitec. This may occur at any time during treatment. In such cases, Renitec should be discontinued promptly and appropriate monitoring should be instituted to ensure complete resolution of symptoms prior to dismissing the patient. Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient.</p><p>&nbsp;</p><p>Very rarely, fatalities have been reported due to angioedema associated with laryngeal oedema or tongue oedema. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, which may include subcutaneous epinephrine solution 1:1000 (0.3 ml to 0.5 ml) and/or measures to ensure a patent airway, should be administered promptly.</p><p>&nbsp;</p><p>Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks.</p><p>&nbsp;</p><p>Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also section 4.3).</p><p>&nbsp;</p><p>Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.</p><p>&nbsp;</p><p><u>Anaphylactoid Reactions during Hymenoptera Desensitisation</u></p><p>Rarely, patients receiving ACE inhibitors during desensitisation with hymenoptera venom have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each desensitisation.</p><p>&nbsp;</p><p><u>Anaphylactoid Reactions during LDL Apheresis</u></p><p>Rarely, patients receiving ACE inhibitors during low density lipoprotein (LDL)-apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions. These reactions were avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.</p><p>&nbsp;</p><p><u>Haemodialysis Patients</u></p><p>Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., AN 69&reg;) and treated concomitantly with an ACE inhibitor. In these patients consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>Diabetic patients treated with oral antidiabetic agents or insulin starting an ACE inhibitor should be told to closely monitor for hypoglycaemia, especially during the first month of combined use (see section 4.5.).</p><p>&nbsp;</p><p><u>Cough</u></p><p>Cough has been reported with the use of ACE inhibitors. Characteristically, the cough is nonproductive, persistent, and resolves after discontinuation of therapy. ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.</p><p>&nbsp;</p><p><u>Surgery/Anaesthesia</u></p><p>In patients undergoing major surgery or during anaesthesia with agents that produce hypotension, enalapril blocks angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p><p>&nbsp;</p><p><u>Hyperkalaemia</u></p><p>Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including enalapril. Risk factors for the development of hyperkalaemia include those with renal insufficiency, worsening of renal function, age (&gt; 70 years), diabetes mellitus, intercurrent events, in particular dehydration, acute cardiac decompensation, metabolic acidosis and concomitant use of potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, or amiloride), potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e.g., heparin). The use of potassium supplements, potassium- sparing diuretics, or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant increase in serum potassium. Hyperkalaemia can cause serious, sometimes fatal arrhythmias. If concomitant use of enalapril and any of the above-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium (see section 4.5).</p><p>&nbsp;</p><p><u>Lithium</u></p><p>The combination of lithium and enalapril is generally not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia, and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>&nbsp;</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Lactose</u></p><p>Renitec contains lactose and therefore should not be used by patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Renitec contains less than 200 mg of lactose per tablet.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There is limited efficacy and safety experience in hypertensive children &gt;6 years old, but no experience in other indications. Limited pharmacokinetic data are available in children above</p><p>2 months of age (see also sections 4.2, 5.1, and 5.2.). Renitec is not recommended in children in other indications than hypertension.</p><p>&nbsp;</p><p>Renitec is not recommended in neonates and in paediatric patients with glomerular filtration rate</p><p>&lt;30 ml/min/1.73 m2, as no data are available (see section 4.2).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>ACE inhibitors should not be initiated during pregnancy. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>&nbsp;</p><p><u>Ethnic differences</u></p><p>As with other angiotensin converting enzyme inhibitors, enalapril is apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of a higher prevalence of low-renin states in the black hypertensive population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Clinical trial data have shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(see sections 4.3, 4.4 and 5.1).</p><p>&nbsp;</p><p><u>Potassium sparing diuretics or potassium supplements</u></p><p>ACE inhibitors attenuate diuretic induced potassium loss. Potassium sparing diuretics (e.g., spironolactone, eplerenone, triamterene or amiloride), potassium supplements, or potassium- containing salt substitutes may lead to significant increases in serum potassium. If concomitant use is indicated because of demonstrated hypokalaemia they should be used with caution and with frequent monitoring of serum potassium (see section 4.4).</p><p>&nbsp;</p><p><u>Diuretics (thiazide or loop diuretics)</u></p><p>Prior treatment with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy with enalapril (see section 4.4). The hypotensive effects can be reduced by discontinuation of the diuretic, by increasing volume or salt intake or by initiating therapy with a low dose of enalapril.</p><p>&nbsp;</p><p><u>Other antihypertensive agents</u></p><p>Concomitant use of these agents may increase the hypotensive effects of enalapril. Concomitant use with nitroglycerine and other nitrates, or other vasodilators, may further reduce blood pressure.</p><p>&nbsp;</p><p><u>Lithium</u></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may further increase lithium levels and enhance the risk of lithium toxicity with ACE inhibitors. Use of enalapril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).</p><p>&nbsp;</p><p><u>Tricyclic antidepressants/Antipsychotics/Anaesthetics/Narcotics</u></p><p>Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).</p><p>&nbsp;</p><p><u>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 (COX-2)</u> <u>Inhibitors</u></p><p>Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclooxygenase-2 inhibitors (COX-2 inhibitors) may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the antihypertensive effect of angiotensin II receptor antagonists or ACE inhibitors may be attenuated by NSAIDs including selective COX-2 inhibitors.</p><p>&nbsp;</p><p>The coadministration of NSAIDs (including COX-2 inhibitors) and angiotensin II receptor antagonists or ACE inhibitors exert an additive effect on the increase in serum potassium, and may result in a deterioration of renal function. These effects are usually reversible. Rarely, acute renal failure may occur, especially in patients with compromised renal function (such as the elderly or patients who are volume-depleted, including those on diuretic therapy). Therefore, the combination should be administered with caution in patients with compromised renal function. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter.</p><p>&nbsp;</p><p><u>Gold</u></p><p>Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including enalapril.</p><p>&nbsp;</p><p><u>Mammalian Target of Rapamycin (mTOR) Inhibitors</u></p><p>Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see section 4.4).</p><p>&nbsp;</p><p><u>Sympathomimetics</u></p><p>Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.</p><p>&nbsp;</p><p><u>Antidiabetics</u></p><p>Epidemiological studies have suggested that concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose- lowering effect with risk of hypoglycaemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>Alcohol</u></p><p>Alcohol enhances the hypotensive effect of ACE inhibitors.</p><p>&nbsp;</p><p><u>Acetyl salicylic acid, thrombolytics and </u><u>b-blockers</u></p><p>Enalapril can be safely administered concomitantly with acetyl salicylic acid (at cardiologic doses), thrombolytics and b-blockers.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u> ACE inhibitors:</p><p>The use of ACE inhibitors is not recommended during the first trimester of pregnancy (see</p><p>section 4.4). The use of ACE inhibitors is contra-indicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Unless continued ACE inhibitor therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.</p><p>&nbsp;</p><p>When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>&nbsp;</p><p>Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Maternal oligohydramnios, presumably representing decreased foetal renal function, has occurred and may result in limb contractures, craniofacial deformations and hypoplastic lung development.</p><p>&nbsp;</p><p>Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>&nbsp;</p><p>Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Limited pharmacokinetic data demonstrate very low concentrations in breast milk (see section 5.2). Although these concentrations seem to be clinically irrelevant, the use of Renitec in breast-feeding is not recommended for preterm infants and for the first few weeks after delivery, because of the hypothetical risk of cardiovascular and renal effects and because there is not enough clinical experience. In case of an older infant, the use of Renitec in breast-feeding mother may be considered if this treatment is necessary for the mother and the child is observed for any adverse effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>The following undesirable effects have been reported for enalapril in clinical studies and in post- marketing experience:</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very</strong><strong> </strong><strong>common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong><strong> </strong><strong>(&ge;1/100 to</strong></p><p><strong>&lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong><strong> </strong><strong>(&ge;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong><strong> </strong><strong>(&ge;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very</strong><strong> rare (&lt;1/10,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not</strong><strong> </strong><strong>known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia (including aplastic and haemolytic)</p></td><td style="vertical-align:top"><p>Neutropenia, decreases in haemoglobin, decreases in haematocrit, thrombocytop enia, agranulocytosi s, bone marrow depression, pancytopenia, lymphadenopa thy, autoimmune diseases</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Endocrine</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome of inappropriate antidiuretic hormone secretion (SIADH)</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypoglycae mia (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Confusion, nervousness, insomnia</p></td><td style="vertical-align:top"><p>Dream abnormality, sleep disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Nervous</em></strong><strong><em> system disorders</em></strong></p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Headache, syncope, taste alteration</p></td><td style="vertical-align:top"><p>Somnolence, paresthesia, vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Eye</em></strong><strong><em> disorders</em></strong></p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Ear</em></strong><strong><em> and labyrinth disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>chest pain, rhythm disturbances, angina pectoris, tachycardia</p></td><td style="vertical-align:top"><p>palpitations, myocardial infarction or cerebrovascu lar accident*, possibly secondary to excessive hypotension in high risk patients (see</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Vascular</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension (including orthostatic hypotension)</p></td><td style="vertical-align:top"><p>Flushing, orthostatic hypotension</p></td><td style="vertical-align:top"><p>Raynaud&rsquo;s phenomenon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Respiratory, thoracic, and mediastinal disorders</em></strong></p></td><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Rhinorrhoea, sore throat and hoarseness, bronchospas m/asthma</p></td><td style="vertical-align:top"><p>Pulmonary infiltrates, rhinitis, allergic alveolitis/eosi nophilia pneumonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Gastrointestina l disorders</em></strong></p></td><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Diarrhoea, abdominal pain</p></td><td style="vertical-align:top"><p>Ileus, pancreatitis, vomiting, dyspepsia, constipation, anorexia, gastric irritations, dry mouth, peptic ulcer</p></td><td style="vertical-align:top"><p>Stomatitis/aph thous ulcerations, glossitis</p></td><td style="vertical-align:top"><p>Intestinal angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic failure, hepatitis &ndash; either hepatocellular or cholestatic, hepatitis including necrosis, cholestasis (including jaundice)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, hypersensitivi ty/angioneurot ic oedema: angioneurotic oedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported (see section 4.4)</p></td><td style="vertical-align:top"><p>Diaphoresis, pruritus, urticaria, alopecia</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens- Johnson syndrome, exfoliative dermatitis, toxic epidermal necrolysis, pemphigus, erythroderma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>A symptom complex has been reported which may include some or all of the following: fever, serositis, vasculitis, myalgia/myositi s, arthralgia/arthri tis, a positive ANA, elevated ESR,</p><p>eosinophilia, and leucocytosis. Rash, photosensitivity</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>or other dermatologic manifestations may occur.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Musculoskeleta l, connective tissue, and bone disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Renal</em></strong><strong><em> </em></strong><strong><em>and</em></strong><strong><em> </em></strong><strong><em>urinary</em></strong><strong><em> </em></strong><strong><em>disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal dysfunction, renal failure, proteinuria</p></td><td style="vertical-align:top"><p>Oliguria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Reproductive system and breast disorders</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Impotence</p></td><td style="vertical-align:top"><p>Gynaecomasti a</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>General</em></strong><strong><em> </em></strong><strong><em>disorders and administration site conditions</em></strong></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Malaise, fever</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalaemi a, increases in serum creatinine</p></td><td style="vertical-align:top"><p>Increases in blood urea, hyponatraemi a</p></td><td style="vertical-align:top"><p>Elevations of liver enzymes, elevations of serum bilirubin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>* Incidence rates were comparable to those in the placebo and active control groups in the clinical trials.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via (The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC). SFDA</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Limited data are available for overdosage in humans. The most prominent features of overdosage reported to date are marked hypotension, beginning some six hours after ingestion of tablets, concomitant with blockade of the renin-angiotensin system, and stupor. Symptoms associated with overdosage of ACE inhibitors may include circulatory shock, electrolyte disturbances, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety, and cough. Serum enalaprilat levels 100- and 200-fold higher than usually seen after therapeutic doses have been reported after ingestion of 300 mg and 440 mg of enalapril, respectively.</p><p>&nbsp;</p><p>The recommended treatment of overdosage is intravenous infusion of normal saline solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. If ingestion is recent, take measures aimed at eliminating enalapril maleate (e.g., emesis, gastric lavage, administration of absorbents, and sodium sulphate). Enalaprilat may be removed from the general circulation by haemodialysis (see section 4.4.). Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin converting enzyme inhibitors, ATC Code: C09A A02</p><p>&nbsp;</p><p>Renitec (enalapril maleate) is the maleate salt of enalapril, a derivative of two amino-acids, L-alanine and L-proline. Angiotensin converting enzyme (ACE) is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the pressor substance angiotensin II. After absorption, enalapril is hydrolysed to enalaprilat, which inhibits ACE. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release), and decreased aldosterone secretion.</p><p>&nbsp;</p><p>ACE is identical to kininase II. Thus Renitec may also block the degradation of bradykinin, a potent vasodepressor peptide. However, the role that this plays in the therapeutic effects of Renitec remains to be elucidated.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>While the mechanism through which Renitec lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, Renitec is antihypertensive even in patients with low-renin hypertension.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Administration of Renitec to patients with hypertension results in a reduction of both supine and standing blood pressure without a significant increase in heart rate.</p><p>&nbsp;</p><p>Symptomatic postural hypotension is infrequent. In some patients the development of optimal blood pressure reduction may require several weeks of therapy. Abrupt withdrawal of Renitec has not been associated with rapid increase in blood pressure.</p><p>&nbsp;</p><p>Effective inhibition of ACE activity usually occurs 2 to 4 hours after oral administration of an individual dose of enalapril. Onset of antihypertensive activity was usually seen at one hour, with peak reduction of blood pressure achieved by 4 to 6 hours after administration. The duration of effect is dose-related. However, at recommended doses, antihypertensive and haemodynamic effects have been shown to be maintained for at least 24 hours.</p><p>&nbsp;</p><p>In haemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate. Following administration of Renitec there was an increase in renal blood flow; glomerular filtration rate was unchanged. There was no evidence of sodium or water retention. However, in patients with low pretreatment glomerular filtration rates, the rates were usually increased.</p><p>&nbsp;</p><p>In short term clinical studies in diabetic and nondiabetic patients with renal disease, decreases in albuminuria and urinary excretion of IgG and total urinary protein were seen after the administration of enalapril.</p><p>&nbsp;</p><p>When given together with thiazide-type diuretics, the blood pressure-lowering effects of Renitec are at least additive. Renitec may reduce or prevent the development of thiazide-induced hypokalaemia.</p><p>&nbsp;</p><p>In patients with heart failure on therapy with digitalis and diuretics, treatment with oral or injection Renitec was associated with decreases in peripheral resistance and blood pressure. Cardiac output increased, while heart rate (usually elevated in patients with heart failure) decreased. Pulmonary capillary wedge pressure was also reduced. Exercise tolerance and severity of heart failure, as</p><p>measured by New York Heart Association criteria, improved. These actions continued during chronic therapy.</p><p>&nbsp;</p><p>In patients with mild to moderate heart failure, enalapril retarded progressive cardiac dilatation/enlargement and failure, as evidenced by reduced left ventricular end diastolic and systolic volumes and improved ejection fraction.</p><p>&nbsp;</p><p><u>Dual Blockade of the renin-angiotensin-aldosterone system (RAAS)</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial), VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>&nbsp;</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>&nbsp;</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>&nbsp;</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>&nbsp;</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>A multicenter, randomised, double-blind, placebo-controlled trial (SOLVD Prevention trial) examined a population with asymptomatic left ventricular dysfunction (LVEF&lt;35%). 4228 patients were randomised to receive either placebo (n=2117) or enalapril (n=2111). In the placebo group, 818 patients had heart failure or died (38.6%) as compared with 630 in the enalapril group (29.8%) (risk reduction: 29%; 95% CI; 21-36%; p&lt;0.001). 518 patients in the placebo group (24.5%) and 434 in the enalapril group (20.6%) died or were hospitalised for new or worsening heart failure (risk reduction 20%; 95% CI; 9-30%; p&lt;0.001).</p><p>&nbsp;</p><p>A multicenter, randomised, double-blind, placebo-controlled trial (SOLVD Treatment trial) examined a population with symptomatic congestive heart failure due to systolic dysfunction (ejection fraction</p><p>&lt;35%). 2569 patients receiving conventional treatment for heart failure were randomly assigned to receive either placebo (n=1284) or enalapril (n=1285). There were 510 deaths in the placebo group (39.7%) as compared with 452 in the enalapril group (35.2%) (reduction in risk, 16%; 95% CI, 5- 26%; p=0.0036). There were 461 cardiovascular deaths in the placebo group as compared with 399 in the enalapril group (risk reduction 18%, 95% CI, 6-28%, p&lt;0.002), mainly due to a decrease of deaths due to progressive heart failure (251 in the placebo group vs 209 in the enalapril group, risk reduction 22%, 95% CI, 6-35%). Fewer patients died or were hospitalised for worsening heart failure (736 in &nbsp;the placebo group and 613 in the enalapril group; risk reduction, 26%; 95% CI, 18-34%; p&lt;0.0001). Overall in SOLVD study, in patients with left ventricular dysfunction, Renitec reduced the risk of</p><p>myocardial infarction by 23% (95% CI, 11&ndash;34%; p&lt;0.001) and reduced the risk of hospitalisation for unstable angina pectoris by 20% (95% CI, 9&ndash;29%; p&lt;0.001).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>There is limited experience of the use in hypertensive paediatric patients &gt;6 years. In a clinical study involving 110 hypertensive paediatric patients 6 to 16 years of age with a body weight &ge;20 kg and a glomerular filtration rate &gt;30 ml/min/1.73 m2, patients who weighed &lt;50 kg received either 0.625, 2.5 or 20 mg of enalapril daily and patients who weighed &sup3;50 kg received either 1.25, 5 or 40 mg of enalapril daily. Enalapril administration once daily lowered trough blood pressure in a dose- dependent manner. The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups (age, Tanner stage, gender, race). However, the lowest doses studied, 0.625 mg and</p><p>1.25 mg, corresponding to an average of 0.02 mg/kg once daily, did not appear to offer consistent antihypertensive efficacy. The maximum dose studied was 0.58 mg/kg (up to 40 mg) once daily. The adverse experience profile for paediatric patients is not different from that seen in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Oral enalapril is rapidly absorbed, with peak serum concentrations of enalapril occurring within one hour. Based on urinary recovery, the extent of absorption of enalapril from oral enalapril tablet is approximately 60%. The absorption of oral Renitec is not influenced by the presence of food in the gastrointestinal tract.</p><p>&nbsp;</p><p>Following absorption, oral enalapril is rapidly and extensively hydrolysed to enalaprilat, a potent angiotensin converting enzyme inhibitor. Peak serum concentrations of enalaprilat occur about</p><p>4 hours after an oral dose of enalapril tablet. The effective half-life for accumulation of enalaprilat following multiple doses of oral enalapril is 11 hours. In subjects with normal renal function, steady- state serum concentrations of enalaprilat were reached after 4 days of treatment.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Over the range of concentrations which are therapeutically relevant, enalaprilat binding to human plasma proteins does not exceed 60%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Except for conversion to enalaprilat, there is no evidence for significant metabolism of enalapril.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Excretion of enalaprilat is primarily renal. The principal components in urine are enalaprilat, accounting for about 40% of the dose, and intact enalapril (about 20%).</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The exposure of enalapril and enalaprilat is increased in patients with renal insufficiency. In patients with mild to moderate renal insufficiency (creatinine clearance 40-60 ml/min) steady state AUC of enalaprilat was approximately two-fold higher than in patients with normal renal function after administration of 5 mg once daily. In severe renal impairment (creatinine clearance &le; 30 ml/min), AUC was increased approximately 8-fold. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency and time to steady state is delayed (see section 4.2.). Enalaprilat may be removed from the general circulation by haemodialysis. The dialysis clearance is 62 ml/min.</p><p>&nbsp;</p><p><u>Children and adolescents</u></p><p>A multiple dose pharmacokinetic study was conducted in 40 hypertensive male and female paediatric patients aged 2 months to &le; 16 years following daily oral administration of 0.07 to 0.14 mg/kg enalapril maleate. There were no major differences in the pharmacokinetics of enalaprilat in children</p><p>&nbsp;</p><p>&nbsp;</p><p>compared with historic data in adults. The data indicate an increase in AUC (normalised to dose per body weight) with increased age; however, an increase in AUC is not observed when data are normalised by body surface area. At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>After a single 20 mg oral dose in five postpartum women the average peak enalapril milk level was</p><p>1.7 &micro;g/L (range 0.54 to 5.9 &micro;g/L) at 4 to 6 hours after the dose. The average peak enalaprilat level was</p><p>1.7 &micro;g/L (range 1.2 to 2.3 &micro;g/L); peaks occurred at various times over the 24 hour period. Using the peak milk level data, the estimated maximum intake of an exclusively breastfed infant would be about 0.16% of the maternal weight-adjusted dosage.</p><p>A woman who had been taking oral enalapril 10 mg daily for 11 months had peak enalapril milk levels of 2 &micro;g/L 4 hours after a dose and peak enalaprilat levels of 0.75 &micro;g/L about 9 hours after the dose. The total amount of enalapril and enalaprilat measured in milk during the 24 hours period was</p><p>1.44 &micro;g/L and 0.63 &micro;g/L of milk respectively.</p><p>Enalaprilat milk levels were undetectable (&lt;0.2 &micro;g/L) 4 hours after a single dose of enalapril 5 mg in one mother and 10 mg in two mothers; enalapril levels were not determined.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Reproductive toxicity studies suggest that enalapril has no effects on fertility and reproductive performance in rats, and is not teratogenic. In a study in which female rats were dosed prior to mating through gestation, an increased incidence of rat pup deaths occurred during lactation. The compound has been shown to cross the placenta and is secreted in milk. Angiotensin converting enzyme inhibitors, as a class, have been shown to be foetotoxic (causing injury and/or death to the foetus) when given in the second or third trimester.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydrogen carbonate corn starch</p><p>Pregelatinised corn starch Magnesium stearate Lactose hydrous</p><p>Iron oxide red (E172) &ndash; 10 mg and 20 mg tablets only Iron oxide yellow (E172) &ndash; 20 mg tablet only</p><p>Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Renitec 5 mg - All-aluminium blister packages containing 2, 14, 20, 28, 28 x 1, 30, 49 x 1, 50, 60, 98,</p><p>or 100 tablets.</p><p>Renitec 10 mg - All-aluminium blister packages containing 28, 49 x 1, 30, 50, 98 or 100 tablets.</p><p>Renitec 20 mg - All-aluminium blister packages containing 10, 14, 20, 28, 28 x 1, 30, 49 x 1, 50, 56,</p><p>60, 84, 90, 98, 100 or 500 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder
Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem
P.O. Box 581 , 2003 PC Haarlem,
The Nethterlands

Manufacturer
Merck Sharp & Dohme, Shotton Lane, Cramlington Northumberland NE23 3JU, 
United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Last partial revision concerns sections 4.4 and 4.5: 8 April 2016.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>